Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aromatherapy Gel for De Quervain Disease
NCT06012097Phase 4
Key facts
- Status
- Recruiting
- Start
- Jun 2024
- Primary completion
- Apr 2026
- Countries
- 1
- Sponsor
- Strasbourg University Hospital
- Modality
- Hydrogel Systems, Transdermal Patches
- Drugs
- aromatherapy gel
- Conditions
- subacute granulomatous thyroiditis (SAT)
01
Overview
Phase 4, randomised, single-blind trial of aromatherapy gel in subacute granulomatous thyroiditis (SAT) (2 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Measure of pain during the Wrist Hyperflexion and Abduction of the Thumb (WHAT) test at Day 84. Started Jun 2024; status: recruiting.
02
Design
2 arms- Study design
- RandomizedSingle-blind
Active Comparator
Diclofenac gel + Splint
Experimental Group
Aromatherapy gel + Splint
03
Who it enrols
Adult patients with unilateral De Quervain's tenosynovitis, excluding those with skin damage, epilepsy, or recent corticosteroid infiltrations.
04
Endpoints
Primary
Measure of pain during the Wrist Hyperflexion and Abduction of the Thumb (WHAT) test
Beyond the preview
Go deeper on NCT06012097.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06012097.